4
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Breast Cancer
- Tumour Sub-type
- Breast Cancer
- Tumour Sub-Group
- HER2+
- Tumour stage
- Locally recurrent unresectable or metastatic
- Combined Agent(s)
- Trastuzumab + docetaxel
- Control Arm
- Trastuzumab + docetaxel + placebo
- Treatment Setting
- HER2-positive locally recurrent unresectable or metastatic breast cancer with no prior anti-HER2 therapy or ChT for metastatic disease
- Trial Name
- CLEOPATRA
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- PFS Control
- 12.4 months
- PFS Gain
- 6.3 months
- PFS HR
- 0.62 (0.52-0.75)
- OS Control
- 40.8 months
- OS Gain
- 16.3 months
- OS HR
- 0.69 (0.58-0.82)
- QoL Comment
- No improvement in global QoL
Final Score (after adjustments)
- Preliminary non-curative score
- 4
- Final non-curative Score
- 4
- Issue date
- 11.12.2018
- Release date
- 11.12.2018
- Last update
- 09.05.2022
ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; HRD, homologus recombination deficiency; HRP, homologous recombination proficient; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; NS, not significant; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression; WT, wild type